Publications by authors named "Brielle Liotta"
Signaling through JAK1 and/or JAK2 is common among tumor and nontumor cells within peripheral T-cell lymphoma (PTCL). No oral therapies are approved for PTCL, and better treatments for relapsed/refractory disease are urgently needed. We conducted a phase 2 study of the JAK1/2 inhibitor ruxolitinib for patients with relapsed/refractory PTCL (n = 45) or mycosis fungoides (MF) (n = 7).
View Article and Find Full Text PDFArticle Synopsis
- A phase 2 study evaluated a new treatment approach called Car-BiRd for multiple myeloma, combining carfilzomib and dexamethasone for induction, followed by lenalidomide and clarithromycin for consolidation, then lenalidomide maintenance.
- The treatment showed a high overall response rate of 94%, with 35% of patients achieving complete responses, although the results fell short of the study's goal of 55%.
- The regimen resulted in manageable low-grade toxicities and lower hematologic side effects compared to traditional combination therapies, demonstrating effectiveness particularly for patients who are not candidates for transplant.
Purpose: We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550).
Methods: Transplant eligible patients with rel/ref cHL following first-line therapy were treated with two to four cycles of pembrolizumab (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m IV, days 1 and 8), vinorelbine (20 mg/m IV, days 1 and 8), and liposomal doxorubicin (15 mg/m, days 1 and 8), given on 21-day cycles.